Agile Therapeutics Inc (STU:0AL)
€ 9.83 0 (0%) Market Cap: 7.41 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 19/100

Agile Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 06:30PM GMT
Release Date Price: €4920 (-2.38%)
Scott Kramer;JPMorgan;Investment Banking Associate

Good morning. My name is Scott Kramer. I'm with the JPMorgan Health Care Investment Banking team. It's my pleasure to introduce to you our next presenter, Al Altomari, Chairman and CEO of Agile Therapeutics.

Alfred F. Altomari
Agile Therapeutics, Inc. - Chairman & CEO

Great. Got it. Thank you, everybody. So on behalf of Agile Therapeutics, we'd like to thank Michael Gaito and the banking team for this invitation and also the conference organizers for all their hospitality. So I'm thrilled to be giving you an update on Agile Therapeutics. This is an important year, as you'll hear in my presentation, for the company. So I hope for those of you who are still designing your portfolios and consider portfolio investments, I hope you'll consider Agile Therapeutics as one of your investments this year.

Before I begin, Agile Therapeutics is a publicly traded company. So throughout my presentation, I will be making forward-looking statements, so I would encourage you to take a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot